![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS No 7146h CAMBRIDGE ANTIBODY TECHNOLOGY 27th February 1998 Announces Phage Display Agreement with Dyax Corp Cambridge Antibody Technology (CAT) has today signed a licence agreement with Dyax Corp of Cambridge, Massachusetts, USA. Under the terms of the agreement Dyax has granted CAT a world-wide, non-exclusive revenue-bearing licence under Dyax patent rights covering phage display for research, development and commercialisation of therapeutic and certain diagnostic products. As part of the Agreement, CAT has granted Dyax certain rights under CAT's phage display patent rights, except in the area of therapeutic antibodies, where CAT has only granted Dyax four options for non-exclusive revenue-bearing licences for therapeutic antibody products not already being developed by CAT or its partners. For further information, please contact: Cambridge Antibody Technology 01763 263 233 David Chiswell Chief Executive Officer John Aston Finance Director HCC De Facto Financial 0171 957 4600 Nicola How HCC De Facto Cambridge 01223 518 093 Andrew Worsfold Notes for Editors 1. CAT's business is based on a world leading platform technology for the rapid isolation of human monoclonal antibodies. The technology has applications both in the development of antibody-based human therapeutic products and as a drug discovery tool, particularly for functional genomics. CAT is capitalising on the strength of its platform technology by building a diverse portfolio of antibody-based human therapeutic products. CAT is also using its platform technology as a drug discovery tool, to seek to secure licenses and collaborative agreements with other pharmaceutical companies, including genomics companies, thereby gaining further access to antibody targets of potential therapeutic interest. CAT had already entered into a number of licence and collaborative agreements with pharmaceutical and biotechnology companies. These include ICOS Genentech, Pfizer, Eli Lilly, Knoll (BASF), Knoll (BASF)/Genetics Institute, Mitsubishi Chemical, Techniclone and ObeSys (with BTG). END MSCAFLSLFAIDFAT
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions